Terms: = Prostate cancer AND ZFHX3, ATBT, 463, ENSG00000140836, Q15911 AND Treatment
23 results:
1. Cost-Effectiveness Analysis for Therapy Sequence in Advanced cancer: A Microsimulation Approach with Application to Metastatic prostate cancer.
Handorf EA; Beck JR; Correa A; Ramamurthy C; Geynisman DM
Med Decis Making; 2023; 43(7-8):949-960. PubMed ID: 37811793
[TBL] [Abstract] [Full Text] [Related]
2. Integrating single-cell and bulk RNA sequencing to predict prognosis and immunotherapy response in prostate cancer.
Wen XY; Wang RY; Yu B; Yang Y; Yang J; Zhang HC
Sci Rep; 2023 Sep; 13(1):15597. PubMed ID: 37730847
[TBL] [Abstract] [Full Text] [Related]
3. Signal Crosstalk and the Role of Estrogen Receptor beta (ERβ) in prostate cancer.
Li J; Liu Q; Jiang C
Med Sci Monit; 2022 Apr; 28():e935599. PubMed ID: 35383138
[TBL] [Abstract] [Full Text] [Related]
4. AR imposes different effects on zfhx3 transcription depending on androgen status in prostate cancer cells.
Fu X; Zhang Z; Liu M; Li J; A J; Fu L; Huang C; Dong JT
J Cell Mol Med; 2022 Feb; 26(3):800-812. PubMed ID: 34953044
[TBL] [Abstract] [Full Text] [Related]
5. Real world treatment utilization patterns in patients with castration-resistant prostate cancer.
Vigneswaran HT; Warnqvist A; Andersson TML; Leval A; Eklund M; Nordström T; Eloranta S; Schain F; Dearden L; Liwing J; Mehra M; Nair S; Pettersson A; Akre O; Aly M
Scand J Urol; 2021 Aug; 55(4):299-306. PubMed ID: 34096469
[TBL] [Abstract] [Full Text] [Related]
6. Cost-effectiveness Analysis of Innovative Therapy for Patients with Newly Diagnosed Hormone-Sensitive Metastatic prostate cancer.
Pelloux-Prayer R; Schiele P; Oudard S; Gravis G; Kleinclauss F; Crehange G; Hennequin C; Morgans AK; Geoffrois L; Limat S; Thiery-Vuillemin A; Nerich V
Clin Genitourin Cancer; 2021 Oct; 19(5):e326-e333. PubMed ID: 33962909
[TBL] [Abstract] [Full Text] [Related]
7. Circulating Tumor Cell Genomic Evolution and Hormone Therapy Outcomes in Men with Metastatic Castration-Resistant prostate cancer.
Gupta S; Halabi S; Kemeny G; Anand M; Giannakakou P; Nanus DM; George DJ; Gregory SG; Armstrong AJ
Mol Cancer Res; 2021 Jun; 19(6):1040-1050. PubMed ID: 33771885
[TBL] [Abstract] [Full Text] [Related]
8. Influence of Sociodemographic Factors on Definitive Intervention Among Low-risk Active Surveillance Patients.
Sayyid RK; Klotz L; Benton JZ; Lodh A; Lambert JH; Woodruff P; Lokeshwar SD; Madi R; Goldberg H; Terris MK; Wallis CJD; Klaassen Z
Urology; 2021 Sep; 155():117-123. PubMed ID: 33577898
[TBL] [Abstract] [Full Text] [Related]
9. Cost-effectiveness of treating head and neck cancer using intensity-modulated radiation therapy: implications for cancer control program in India.
Chauhan AS; Prinja S; Ghoshal S; Verma R
Int J Technol Assess Health Care; 2020 Oct; 36(5):492-499. PubMed ID: 32962782
[TBL] [Abstract] [Full Text] [Related]
10. An organoid-based drug screening identified a menin-MLL inhibitor for endometrial cancer through regulating the HIF pathway.
Chen J; Zhao L; Peng H; Dai S; Quan Y; Wang M; Wang J; Bi Z; Zheng Y; Zhou S; Liu Y; Chen C; Na F
Cancer Gene Ther; 2021 Feb; 28(1-2):112-125. PubMed ID: 32632269
[TBL] [Abstract] [Full Text] [Related]
11. Plasma cell-free DNA-based predictors of response to abiraterone acetate/prednisone and prognostic factors in metastatic castration-resistant prostate cancer.
Du M; Tian Y; Tan W; Wang L; Wang L; Kilari D; Huang CC; Wang L; Kohli M
Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):705-713. PubMed ID: 32203070
[TBL] [Abstract] [Full Text] [Related]
12. Systematic review and meta-analysis of patient reported outcomes for nurse-led models of survivorship care for adult cancer patients.
Monterosso L; Platt V; Bulsara M; Berg M
Cancer Treat Rev; 2019 Feb; 73():62-72. PubMed ID: 30639801
[TBL] [Abstract] [Full Text] [Related]
13. The Health Impact of Adult Cervical Deformity in Patients Presenting for Surgical treatment: Comparison to United States Population Norms and Chronic Disease States Based on the EuroQuol-5 Dimensions Questionnaire.
Smith JS; Line B; Bess S; Shaffrey CI; Kim HJ; Mundis G; Scheer JK; Klineberg E; O'Brien M; Hostin R; Gupta M; Daniels A; Kelly M; Gum JL; Schwab FJ; Lafage V; Lafage R; Ailon T; Passias P; Protopsaltis T; Albert TJ; Riew KD; Hart R; Burton D; Deviren V; Ames CP; Group ISS
Neurosurgery; 2017 May; 80(5):716-725. PubMed ID: 28368524
[TBL] [Abstract] [Full Text] [Related]
14. Laparoscopic versus open nephroureterectomy to treat localized and/or locally advanced upper tract urothelial carcinoma: oncological outcomes from a multicenter study.
Liu JY; Dai YB; Zhou FJ; Long Z; Li YH; Xie D; Liu B; Tang J; Tan J; Yao K; He LY
BMC Surg; 2017 Jan; 17(1):8. PubMed ID: 28095848
[TBL] [Abstract] [Full Text] [Related]
15. Factors predicting efficacy and adverse effects of enzalutamide in Japanese patients with castration-resistant prostate cancer: results of retrospective multi-institutional study.
Terada N; Akamatsu S; Okada Y; Negoro H; Kobayashi T; Yamasaki T; Matsui Y; Inoue T; Kamba T; Ogawa O
Int J Clin Oncol; 2016 Dec; 21(6):1155-1161. PubMed ID: 27351872
[TBL] [Abstract] [Full Text] [Related]
16. RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1.
Prensner JR; Zhao S; Erho N; Schipper M; Iyer MK; Dhanasekaran SM; Magi-Galluzzi C; Mehra R; Sahu A; Siddiqui J; Davicioni E; Den RB; Dicker AP; Karnes RJ; Wei JT; Klein EA; Jenkins RB; Chinnaiyan AM; Feng FY
Lancet Oncol; 2014 Dec; 15(13):1469-1480. PubMed ID: 25456366
[TBL] [Abstract] [Full Text] [Related]
17. prostate-specific antigen decline during salvage radiation therapy following prostatectomy is associated with reduced biochemical failure.
Kabarriti R; Ohri N; Hannan R; Tishbi N; Baliga S; McGovern KP; Mourad WF; Ghavamian R; Kalnicki S; Guha C; Garg MK
Pract Radiat Oncol; 2014; 4(6):409-14. PubMed ID: 25407863
[TBL] [Abstract] [Full Text] [Related]
18. Identification of microRNAs differentially expressed in prostatic secretions of patients with prostate cancer.
Guzel E; Karatas OF; Semercioz A; Ekici S; Aykan S; Yentur S; Creighton CJ; Ittmann M; Ozen M
Int J Cancer; 2015 Feb; 136(4):875-9. PubMed ID: 24976077
[TBL] [Abstract] [Full Text] [Related]
19. Intermittent versus continuous cyproterone acetate in bone metastatic prostate cancer: results of a randomized trial.
Verhagen PC; Wildhagen MF; Verkerk AM; Vjaters E; Pagi H; Kukk L; Bratus D; Fiala R; Bangma CH; Schröder FH; Mickisch GH
World J Urol; 2014 Oct; 32(5):1287-94. PubMed ID: 24258313
[TBL] [Abstract] [Full Text] [Related]
20. Natural history of clinically staged low- and intermediate-risk prostate cancer treated with monotherapeutic permanent interstitial brachytherapy.
Taira AV; Merrick GS; Galbreath RW; Wallner KE; Butler WM
Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):349-54. PubMed ID: 19467793
[TBL] [Abstract] [Full Text] [Related]
[Next]
